Company intelligence / Profile preview
Rgene Corporation
Taiwan
- Ownership
- Private
- Development stage
- Other
01
Overview
Rgene Corporation has advanced three oncology drug candidates, including BLEX 404 (maitake mushroom extract), through Phase 2 clinical studies for multiple solid tumor indications. Early trials conducted at Memorial Sloan Kettering Cancer Center demonstrated safety and immunological activity. Rgene has entered licensing and co-development agreements for further development and commercialization, notably with ABVC BioPharma and OncoX. No pivotal/Phase 3 efficacy data are reported yet.[1][3]
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeImmunostimulantBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ABVC BioPharmaOncoX
Beyond the preview
Go deeper on Rgene Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rgene Corporation.